Crestline Management LP lifted its stake in Heron Therapeutics Inc (NASDAQ:HRTX) by 190.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 116,290 shares of the biotechnology company’s stock after acquiring an additional 76,212 shares during the quarter. Crestline Management LP owned approximately 0.18% of Heron Therapeutics worth $2,105,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Alyeska Investment Group L.P. increased its stake in shares of Heron Therapeutics by 9.5% in the third quarter. Alyeska Investment Group L.P. now owns 754,657 shares of the biotechnology company’s stock worth $12,188,000 after acquiring an additional 65,260 shares during the last quarter. Deltec Asset Management LLC acquired a new position in Heron Therapeutics during the fourth quarter worth $2,118,000. Swiss National Bank increased its position in Heron Therapeutics by 25.5% during the fourth quarter. Swiss National Bank now owns 98,500 shares of the biotechnology company’s stock worth $1,783,000 after buying an additional 20,000 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in Heron Therapeutics by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock worth $482,000 after buying an additional 8,135 shares during the last quarter. Finally, Claraphi Advisory Network LLC acquired a new position in Heron Therapeutics during the fourth quarter worth $335,000.
Heron Therapeutics Inc (NASDAQ:HRTX) traded up $0.15 during mid-day trading on Wednesday, reaching $24.20. 158,623 shares of the company’s stock were exchanged, compared to its average volume of 971,083. Heron Therapeutics Inc has a one year low of $12.70 and a one year high of $24.80. The company has a market capitalization of $1,486.91, a PE ratio of -6.57 and a beta of 1.87.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total transaction of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares in the company, valued at $151,680. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 19.93% of the stock is owned by corporate insiders.
Several equities analysts have commented on HRTX shares. Mizuho reissued a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a research report on Friday, December 8th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 15th. BidaskClub raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 20th. Oppenheimer set a $27.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. Finally, ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $30.08.
TRADEMARK VIOLATION NOTICE: “Crestline Management LP Boosts Stake in Heron Therapeutics Inc (HRTX)” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/14/crestline-management-lp-boosts-stake-in-heron-therapeutics-inc-hrtx.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.